Cargando…
VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma
The addition of cytotoxic drugs to high-dose melphalan as a preparative regimen for autologous stem cell transplantation in multiple myeloma has not resulted in superior activity. Although novel agents have significantly improved outcome in multiple myeloma, their role in preparative regimens remain...
Autores principales: | Nadiminti, Kalyan, Singh Abbi, Kamal Kant, Mott, Sarah L, Dozeman, Lindsay, Tricot, Annick, Schultz, Allyson, Behrends, Sonya, Zhan, Fenghuang, Tricot, Guido |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5229169/ https://www.ncbi.nlm.nih.gov/pubmed/28123303 http://dx.doi.org/10.2147/OTT.S112423 |
Ejemplares similares
-
Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma
por: Zhan, Xin, et al.
Publicado: (2017) -
Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching
por: Moreau, Philippe, et al.
Publicado: (2020) -
Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation
por: Fouquet, Guillemette, et al.
Publicado: (2014) -
Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma
por: Lee, Yoo Jin, et al.
Publicado: (2019) -
The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan
por: Du, Jeng-Shiun, et al.
Publicado: (2022)